Personalized antisense oligonucleotide therapy for LMNB1-associated Autosomal Dominant Leukodystrophy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Personalized antisense oligonucleotide therapy for LMNB1-associated Autosomal Dominant Leukodystrophy, covering 2025-05-04 to 2025-05-04. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD) [Phase 1, Phase 2]